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Psoriasis is an immune-mediated inflammatory di-
sease, which, in studies among adults, have been 
shown to cluster with autoimmune disease. The aim 
of this cross-sectional register study was to examine 
possible associations between 9 pre-selected autoim-
mune diseases and psoriasis in children and adoles-
cents. The study population consisted of all individuals 
living in Denmark, age under 18 years on 31 Decem-
ber 2012. A total of 1,925 children and adolescents 
with psoriasis and 1,194,712 without psoriasis were 
identified. Psoriatic arthritis (adjusted odds ratio (OR) 
10.08; 7.97–12.74), rheumatoid arthritis (adjusted 
OR 6.61; 2.75–15.87) and vitiligo (adjusted OR 4.76; 
1.71–13.20) showed strong associations with psoria-
sis. In addition to increased risk of selected autoimmu-
ne diseases, the presence of psoriasis was associated 
with increased risk of multiple concurrent autoimmu-
ne diseases compared with children and adolescents 
with out psoriasis. Clinicians should be aware of ex-
tracutaneous symptoms when treating children and 
adole scents with psoriasis.
Key words: psoriasis; autoimmune disease; children; adoles-
cents; comorbidity.
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Psoriasis is chronic inflammatory skin condition with an autoimmune pathogenetic component and 
a strong, but complex, genetic inheritance (1, 2). The 
estimated prevalence of psoriasis in the western world 
is 3–4% in adults and 0.4–1.37% in children and adole­
scents (henceforth “children”) (3–7). The prevalence 
rate increases approximately linearly, from 0.12% at an 
age of 1 year to 1.24% at 18 years of age (3). Incidence 
of psoriasis is bimodal, with a large peak at 16–22 years 
and a smaller peak at 57–60 years, probably reflecting 
different disease entities (8). The disease can be debilita­
ting for patients due to pruritus and visible disfiguration 
resulting from presence of red plaques with silvery scales, 
in turn leading to decreased quality of life (9). In addition, 
patients with psoriasis have an increased risk of several 
comorbidities, such as cardiovascular disease, metabolic 
syndrome, and psoriatic arthritis (10–18).
Studies suggest that some of the comorbidities and as­
sociated risk factors that are seen in adults with psoriasis 
may also be present in children with psoriasis. Indeed, 
studies have suggested increased presence of arterial 
hypertension, metabolic syndrome, and autoimmune 
diseases, including rheumatoid arthritis and Crohn’s 
disease, in paediatric psoriasis (3, 19–28). 
Autoimmune diseases, such as rheumatoid arthritis 
and inflammatory bowel disease (IBD), have a profound 
negative effect on quality of life (29, 30). They are there­
fore a potential additional disease burden to keep in 
mind when treating patients with psoriasis. Autoimmune 
diseases display a heightened immune response against 
the person’s own tissue, cells, and cellular components, 
such as DNA, keratin, or, for psoriasis, a melanocytic 
autoantigen. A recent study confirmed that psoriasis 
shares genetic susceptibility loci with a range of autoim­
mune diseases including IBD (2, 31). In order to further 
examine the risk of concomitant autoimmune disease 
and clustering of autoimmune diseases in children with 
psoriasis compared with healthy controls, we conducted 
a cross­sectional study using the total paediatric popula­
tion in Denmark.
METHODS
Population
All inhabitants under the age of 18 years who were alive and 
resident in Denmark on 31 December 2012 were identified. All 
residents in Denmark are assigned a unique personal 10-digit iden­
tification number at birth or immigration, which enables linkage 
on the individual level between different Danish administrative 
registers. This study used data from the Danish Civil Registration 
System, the Danish National Patient Register, and the Danish Na­
tional Prescription Registry. Data on age, sex, vital- and migration 
status were available from the Danish Civil Registration System 
(32). Established in 1978, the Danish National Patient Register 
contains information on all hospital­based inpatient and, since 
1994, outpatient consultations. Diagnosis are recorded according 
to the International Classification of Diseases, 8th Revision (ICD-
8) until 1994, and the 10th Revision (ICD-10) thereafter (33). 
Information on psoriasis and a number of autoimmune diseases 
was obtained from here. The Danish National Prescription Re­
gistry contains detailed information on the individual level on 
every Danish pharmacy-dispensed medication since 1994, coded 
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in accordance with the Anatomical Therapeutic Chemical (ATC) 
classification system (34).
Lifetime psoriasis was defined as having either an ICD code 
of psoriasis (ICD-10 L40, not including L40.5 arthropathic pso­
riasis) or by the second claimed prescription of topical vitamin 
D analogues (ATC code D05AX). Topical vitamin D analogues 
are the favoured first-line psoriasis treatment in Denmark and are 
registered exclusively for psoriasis. The use of prescription claims 
allowed us to also identify milder psoriasis cases not treated in 
a hospital setting. The second claimed prescription was used to 
ensure persistent medical therapy. Children with life­time psoriasis 
were compared, with respect to life­time diagnosis of 9 selected 
autoimmune diseases, with children without psoriasis.
Information on the life­experience of the 9 autoimmune diseases 
in the Danish National Patient Register was traced. The 9 diseases 
of interest were a priori selected based on paediatric relevance 
(Table I). We decided to group together psoriatic arthritis, juvenile 
psoriatic arthritis, and juvenile idiopathic arthritis (JIA) since 
their clinical signs and symptoms may be difficult to distinguish 
in young patients (35).
Statistical analysis
For baseline characteristics means and standard deviations (SDs) 
were used to describe continuous variables, and frequencies and 
percentages for categorical variables. Logistic regression was 
used to estimate crude and adjusted odds ratios (ORs) (in which 
age, sex, and healthcare consumption were considered) for the 
correlation between a psoriasis diagnosis and other autoimmune 
diseases. Healthcare consumption was defined as the number of 
dermatology visits. A significance level of 0.05 was used and 
results were reported with 95% confidence intervals (95% CIs) 
where applicable. All analyses were performed using SAS statis­
tical software version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and STATA software version 13.0 (StataCorp, College Station, 
TX, USA).
This cross­sectional study of childhood co­existence of psoriasis 
and autoimmune diseases was undertaken in accordance with the 
“Strengthening the Reporting of Observational Studies in Epide­
miology (STROBE)” statement (36). Approval was obtained from 
the Danish Data Protection Agency (ref. 2007-58-0015, int. ref. 
GEH-2014-018, I-Suite 02736), while approval by The National 
Committee on Health Research Ethics is not required for register 
studies in Denmark.
RESULTS
A total of 1,925 children with a diagnosis of psoriasis 
and 1,194,712 children without such a diagnosis (Table 
II) were identified. The majority of the study population 
was of Danish descent. Children with psoriasis were more 
likely to be female (54.7% vs. 48.8%). Adjusting for age, 
sex, and healthcare consumption showed similar results 
as when adjusting for age and sex only. The presented 
results below are adjusted for age, sex and healthcare 
consumption, which give the most conservative esti­
Table I. Included autoimmune diseases 
Autoimmune disease ICD-10 code
Psoriatic arthritisa M07.0-3, M08, M09.0
Rheumatoid arthritis M05, M06
Unspecified IBD Patients with both K50 and K51
Crohn’s disease K50
Ulcerative colitis K51
Coeliac disease K90.0
Type 1 diabetes E10
Autoimmune thyroiditis E06.3
Vitiligo L80
aIncludes psoriatic arthritis, juvenile idiopathic arthritis, and juvenile psoriatic 
arthritis.
IBD: inflammatory bowel disease; ICD-10: International Classification of Diseases, 
10th Revision.
Table II. Demographics of the children with psoriasis in the general 
population
General population
(n = 1,194,712)
Psoriasis
(n = 1,925)
Age, years, mean (SD) 9.2 (5.2) 13.8 (3.4)
Sex, n (%)
  Girls 582,382 (48.8) 1,053 (54.7)
  Boys 612,330 (51.2) 872 (45.3)
Region of origin, n (%)
  Scandinavian 1,070,853 (89.6) 1,696 (88.1)
  Western/Southern Europe 34,410 (2.9) 67 (3.5)
  Africa 18,500 (1.6) 26 (1.4)
  America 2,147 (0.2) 0 (0.0)
  Asia 54,374 (4.6) 116 (6.0)
  Oceania 211 (0.0) 0 (0.0)
  Eastern Europe 13,825 (1.2) 20 (1.0)
  Other/unknown 392 (0.03) 0 (0.0)
Native, n (%) 1,066,942 (89.3) 1,692 (87.9)
Migrant, n (%) 29,469 (2.5) 43 (2.2)
≥ 1 parent were migrants 98,246 (8.2) 190 (9.9)
SD: standard deviation.
Table III. Results showing crude and adjusted associations between psoriasis and included autoimmune diseases
General 
population
n (%)
Psoriasis
n (%)
Crude 
OR 95% CI p-value
Adjusted 
ORb 95% CI p-value
Adjusted 
ORc 95% CI p-value
Psoriatic arthritisa 2,668 (0.2) 81 (4.2) 19.63 15.66–24.60 < 0.0001 12.33 9.82–15.48 < 0.0001 10.08 7.97–12.74 < 0.0001
Rheumatoid arthritis 251 (0.02) 6 (0.31) 14.88 6.61–33.48 < 0.0001 8.12 3.60–18.33 < 0.0001 6.61 2.75–15.87 < 0.0001
Unspecified IBD 182 (0.02) 3 (0.16) 10.24 3.27–32.09 0.0001 5.04 1.60–15.81 0.0056 3.67 1.01–13.35 0.0488
Crohn’s disease 534 (0.04) 4 (0.21) 4.66 1.74–12.47 0.0022 2.64 0.98–7.07 0.0539 1.51 0.47–4.88 0.4868
Ulcerative colitis 501 (0.04) 3 (0.16) 3.72 1.19–11.58 0.0234 2.11 0.68–6.57 0.1989 1.83 0.56–6.00 0.3205
Celiac disease 1,723 (0.14) 7 (0.36) 2.53 1.20–5.32 0.0146 1.77 0.84–3.72 0.1336 1.15 0.50–2.63 0.7439
Type 1 diabetes 2,529 (0.21) 10 (0.52) 2.46 1.32–4.59 0.0046 1.47 0.79–2.74 0.2280 1.08 0.56–2.12 0.8111
Autoimmune thyroiditis 263 (0.02) 4 (0.21) 9.46 3.52–25.41 < 0.0001 4.38 1.63–11.78 0.0035 3.12 1.01–9.63 0.0481
Vitiligo 199 (0.02) 6 (0.31) 18.77 8.32–42.33 < 0.0001 11.74 5.18–26.60 < 0.0001 4.76 1.71–13.20 0.0027
One of the above 
autoimmune diseases
8,046 (0.7) 102 (5.3) 8.30 6.79–10.14 < 0.0001 5.35 4.34–6.49 < 0.0001 4.40 3.56–5.43 < 0.0001
Two or more of the above 
autoimmune diseases
408 (0.0) 11 (0.6) 17.65 9.68–32.18 < 0.0001 9.83 5.38–17.97 < 0.0001 7.27 3.91–13.50 < 0.0001
aIncludes psoriatic arthritis, juvenile idiopathic arthritis, and juvenile psoriatic arthritis; badjusted for age and sex; cadjusted for age, sex, and number of dermatology visits.
OR: odds ratio; IBD: inflammatory bowel disease.
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mate. All results are shown in Table III. In general, 
both rheumatoid arthritis and the combined psoriatic 
arthritis group showed strong associations with psoria­
sis. As expected, psoriatic arthritis had the most evident 
association (adjusted OR 10.08; 7.97–12.74), while the 
association was less pronounced for rheumatoid arthritis 
(adjusted OR 6.61; 2.75–15.87). Vitiligo (adjusted OR 
4.76; 1.71–13.20) and autoimmune thyroiditis (adjusted 
OR 3.12; 1.01–9.63) were also more prevalent among 
children with psoriasis. Among the remaining diseases; 
IBDs, coeliac disease, and type 1 diabetes, only the 
category of “unspecified IBD” remained significantly 
associated with psoriasis after adjustment for confoun­
ding factors (adjusted OR 3.67; 1.01–13.35). Overall, 
psoriasis was significantly associated with having at least 
one autoimmune disease (adjusted OR 4.40; 3.56–5.43). 
Furthermore, having more than one autoimmune disease 
showed an even stronger association with psoriasis (ad­
justed OR 7.27; 3.91–13.50) (Table III).
DISCUSSION
In our study, psoriatic arthritis, rheumatoid arthritis, 
vitiligo, autoimmune thyroiditis, and unspecified IBD 
were significantly associated with psoriasis in children. 
Furthermore, children with psoriasis had a significantly 
higher risk of having multiple concurring autoimmune 
diseases compared with children without psoriasis. Our 
results suggest that psoriasis in children is associated 
with some, but not all, of the autoimmune diseases pre­
viously shown in adults (10, 37). Only 2 previous studies 
in children have included narrow ungrouped selections 
of autoimmune diseases, but both studies lacked adjust­
ments for confounding factors including age, sex, and 
healthcare consumption (3, 28).
Adjustment for respectively age and sex, and age, 
sex, and healthcare consumption yielded similar results 
with the latter being the more conservative. As expected, 
psoriatic arthritis was strongly associated with psoriasis, 
but also rheumatoid arthritis was significantly associa­
ted with psoriasis, which confirms previous findings in 
children and adults (3, 10). Children with psoriasis had 
an increased risk of vitiligo, which is in agreement with 
observations in adults (10, 37). However, a study in 
children could not show this (28). One reason for the 
observed association between psoriasis and vitiligo 
could be due to misclassification of healed depigmented 
psoriasis lesions, but this explanation seems less likely, 
since the diagnosis of vitiligo in our study is based on a 
hospital diagnosis and is therefore probably given by a 
trained dermatologist. Conversely, vitiligo may be iden­
tified more often, since the children with psoriasis are 
seen by dermatologists. We did not find the individual 
IBDs (Crohn’s disease and ulcerative colitis) associated 
with psoriasis, even though previous studies in adults 
have shown this (10, 38). Previous studies in children 
have shown conflicting results. In one study Crohn’s 
disease was found to be more prevalent in children with 
psoriasis, while another paediatric study failed to show 
a significant association between the respective IBDs 
and psoriasis (3, 28). In contrast to previous studies, we 
did not find a significant association between coeliac 
disease and psoriasis (39, 40). One possible explanation 
for the above­mentioned discrepancies could be that our 
study population is inherently young. The children have 
therefore not reached an age where the prevalence of the 
studied autoimmune diseases has reached a level where 
a possible association can be shown. This could either 
be because the diseases have not yet developed or due 
to a delayed hospital diagnosis based on still unspecific 
symptoms. For example, in the case of IBD the incidence 
rate does not peak until 15–29 years of age, with the gra­
dient of the curve increasing sharply to this point (41). 
The study by Augustin et al. (3), showing a significant 
association between Crohn’s disease and psoriasis in 
children, did not control for any potential confounding 
factors; consequently, their results were similar to our 
unadjusted results. A modest, but significant, association 
was found between psoriasis and autoimmune thyroiditis 
in children, even though such an association has not been 
found in adults with psoriasis (42, 43). In our study, we 
did not find any association between psoriasis and type 
1 diabetes; an observation in accordance with previous 
findings from adults with psoriasis (10). The previous 
studies on the association between psoriasis and diabe­
tes in children have focused either on type 2 diabetes or 
diabetes in general with no discrimination between type 
1 and type 2 diabetes (3, 28, 44). Interestingly, the results 
of the current study suggest that children with psoriasis 
in general have a higher risk of having autoimmune di­
seases. This clustering of autoimmune disease has also 
been shown in adults with psoriasis and is supported by 
the fact that many of these autoimmune diseases share 
genetic loci (10, 31, 45). The results of the current study 
also suggest that psoriasis is associated with an even 
higher risk of having multiple autoimmune diseases, and 
this has not been proven in adults (10).
The current study has several strengths; it was based 
on a large nationwide register; we were able to include 
also milder psoriasis cases via vitamin D analogue usage; 
and it was possible to adjust for important confounders. 
All inhabitants in Denmark have equal access to tax-
supported healthcare without charge, including treatment 
in hospital­based settings and by general practitioners. 
Selection bias was thus minimized. Although vitamin 
D analogues are not officially recommended for use 
in children, a recent consensus paper confirmed that 
practicing dermatologists agree on and recommend the 
use of topical vitamin D analogues as a first-choice in 
paediatric psoriasis (34). A recent review also demon­
strated that topical vitamin D analogues are efficacious 
and generally safe for paediatric use (35). Due to the 
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natural history of many autoimmune diseases, it may 
be difficult to determine the exact time of disease onset, 
e.g. patients may have had symptoms for years before 
seeking medical attention or before a correct diagnosis is 
assigned. Thus, we opted for a cross­sectional study de­
sign as this does not include temporal assessment. All the 
investigated associations were found to be significant in 
the unadjusted form, which emphasizes the importance of 
considering confounding factors. In particular, healthcare 
consumption among patients with psoriasis could bias 
the observed comorbidity, due to an increased number 
of doctor’s visits compared with the general population. 
This is supported by the fact that all results are more 
conservative when healthcare consumption is included 
in the model (Table III). The current study is limited by 
its descriptive nature and offers no causal explanations. 
The provided data are very much dependent on correct 
clinical diagnosis, but the included autoimmune diseases 
are most likely diagnosed by hospital specialists in re­
levant fields, e.g. arthritis by rheumatologists, IBD by 
gastroenterologists, etc. The decision to group together 
psoriatic arthritis, juvenile psoriatic arthritis, and JIA on 
the basis of diagnostic difficulties is supported by the 
fact that a sub­analysis showed that some children with 
psoriasis had a diagnosis of JIA, while some children 
without psoriasis had a diagnosis of psoriatic arthritis 
(data not shown). Furthermore, clinical presentation 
of the aforementioned paediatric diseases can be very 
similar and thus difficult to distinguish (35). Since 
Crohn’s disease and ulcerative colitis are more easily 
distinguished through different diagnostic methods (e.g. 
endoscopy and histology) we decided not to group them 
together in a single IBD entity. Furthermore, the respec­
tive diseases have different genetic and environmental 
risk factors (46). The prevalence of psoriasis in children 
is relatively low, and most of the autoimmune diseases 
studied are themselves rare. Consequently, the absolute 
number of observed children with concomitant autoim­
mune diseases is small. This yields broad confidence in­
tervals, and the results should be interpreted accordingly. 
The absolute numbers of cases in the psoriasis group for 
both autoimmune thyroiditis and the categories of IBD 
are between 3 and 4. Therefore, just one case could be 
decisive. With regards to generalizability, our study is 
predominantly in children of Danish descent, and the 
results on clustering of autoimmune disease are in agree­
ment with previous findings in adults (10).
Conclusion
Autoimmune diseases are known to cluster and can have 
a severe effect on quality of life. This study shows that 
children and adolescents with psoriasis are at increased 
risk of having one or more selected autoimmune diseases 
compared with the general population. Although many of 
these conditions remain rare, clinicians should keep these 
associations in mind when treating psoriasis in children, 
as they may add to the total disease burden. In particular, 
focus on extra­cutaneous symptoms is advised.
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